Introduction {#Sec1}
============

Squamous cell carcinomas of the head and neck (HNSCC) remains a significant therapeutic challenge, and the effectiveness of current treatments remains the same as it was 40 years ago \[[@CR1]\]. According to a concept put forward by Folkman in 1971, tumor growth depends on local neo-angiogenesis \[[@CR2]\]. Assessments of angiogenesis in tumors, including HNSCCs, require application of reliable indicators, or markers of angiogenesis, which may be measured using methods such as immunohistochemistry (IHC) with antibodies specific for antigens present on the vascular endothelium, including CD34 or CD105. As proposed by Weidner et al., microvessel density (MCD) is calculated as a mean number of microvessels identified using a light microscope with the known field diameter. These investigators were the first to report an association between MVD and prognosis in breast cancers \[[@CR3]\]. This report generated much interest and initiated a search for similar associations in a variety of other neoplasms in hope of identifying new prognostic factors.

CD34 is a membrane glycoprotein found on the external surface of endothelial cells. During angiogenesis, the CD34 protein is responsible for adhesion of leukocytes to the internal surface of a vascular wall and for migration of vascular endothelial cells \[[@CR4]\]. CD34 is expressed in all endothelial cells during proliferation as well as in the G~0~ stage, and anti-CD34 Abs react with the largest number of endothelial cells compared to other antibodies used in studies of tumor angiogenesis. However, anti-CD34 Abs may also interact with various elements of the matrix, limiting their specificity in MVD assessments \[[@CR5]\].

The CD105 antigen (endoglin) is a homodimeric membrane glycoprotein consisting of two subunits connected by a disulfide bridge. CD105 is a component of the TGF-ß receptor complex \[[@CR6]\]. CD105 is present mainly on the f vascular endothelium, but may also be also found on the surface of hematopoietic cells and fibroblasts \[[@CR7]\]. CD105 glycoprotein is exclusively expressed on actively proliferating endothelial cells, where endoglin is involved in the control of cell proliferation, migration, and formation of new vessels \[[@CR7]\]. The exact role of endoglin in angiogenesis remains unclear, although it has been demonstrated that the presence of endoglin in the tumor vascular endothelium is a negative predictive factor in various types of solid tumors \[[@CR8]\].

The reports of MVD in head and neck cancers show high levels of variability, which might reflect a diversity in detection methodologies used in the previous studies. The goal of this work was to evaluate MVD in HNSCCs, using tissue microarrays (TMA) to ensure the uniform tissue quality for a reliable MVD measurements and to assess the relationship between the MVD values and selected clinical and pathomorphological features of the disease. These data were expected to indicate whether MVD plays a role in HNSCC as a potential predictive marker of survival.

Materials and methods {#Sec2}
=====================

A retrospective analysis of patients with primary HNSCC (*n* = 49) and patients with dysplasia of the endothelium in the upper respiratory tract (*n* = 11) was conducted. Control group consisted of mucus membranes acquired from patients undergoing soft palate surgery due to obstructive sleep apnea (OSA) (*n* = 12). All patients were treated at the Department of Otolaryngology of the Faculty of Medicine and Dentistry at the Medical University of Warsaw between 2007 and 2011. The study was approved by the Ethics Committee at the Medical University of Warsaw, and all patients signed informed consent forms (AKBE/50/12\# to T.S.). Clinicopathological assessment was conducted based on the TNM and UICC classifications. Only patients fulfilling the requirement for 5-year follow-up were included in this study (Table [1](#Tab1){ref-type="table"}).

Table 1Clinicopathological characteristics of the HNSCC patients with primary tumors as well as genders and ages of healthy controls included in this studyCharacteristicsHNSCC patientsDysplasia patientsHealthy controls*n* = 49(%)*n* = 11(%)*n* = 12(%)Sex Male459298212100 Female48218--Age Average ± SD60.3 ± 8.8161.8 ± 6.2555.4 ± 8.98 Median60.0058.5063.00Tumor site Larynx and hypopharynx3878 Oral cavity and tongue1122Clinicopathological characteristics Tumor size  T148  T2918  T31939  T41735 Tumor differentiation  G124  G23980  G3816 Nodal involvement  N+1939  N−3061 Nodal involvement  N1737  N2a421  N2b737  N2c15 Treatment  Tumor resection2041  Tumor resection + neck dissection2959 Stage  I24  II510  III1633  IVa2653

Among the group of patients alive at the time of the analysis, the follow-up period was 60--104 months.

Tissue microarrays {#Sec3}
------------------

TMA were prepared using the available stored histopathological samples. Single paraffin blocks containing tissue material obtained from patients with HNSCC were prepared. For each tumor, the material was collected from at least two sites indicated by the pathologist as a neoplastic focus. An individual slice obtained using the TMA method was placed on the microscope slide and colored as a single microscope specimen.

Immunohistochemistry {#Sec4}
--------------------

To visualize staining, we used the Novolink Polymer Detection System (Novocastra and Dako) according to the producer's recommendations. To identify the cells of vascular origin, we used the murine monoclonal antibody antiCD34 Class II (clone:QBEnd 10) at 1:50 dilution (Dako); murine monoclonal antibody antiCD105 (clone:SN6h) at 1:25 dilution (Dako). Slices were deparaffinized in xylene, and dehydrated in ethanol solutions and distilled water. They were incubated in the TBS buffer (0.1 mmol/l Tris buffer solution, pH = 7.6) for 10 min at a room temperature (RT). To uncover relevant antigen determinants, slides were incubated with TRS High pH buffer (Target Retrieval Solution, pH 9) (Novocastra). Endogenous peroxidase activity was blocked with a 3% hydrogen peroxide solution (Protein Block by Novolink Polymer Detection System, Novocastra). Incubation with reagents was conducted overnight in a moist chamber of the refrigerator at a 4 °C. Each TMA was covered with 300 µl of antibodies. Negative controls consisted of specimen where IHC Diluent (Novocastra) was used instead of a primary antibody. Positive controls consisted of reactions conducted on tissues recommended by the producer of the antibody.

Specimens were assessed blinded using a light microscope by two independent examiners (T.S. and M.J.S.) and the results were averaged. MVD was calculated as an arithmetic mean of the number of microvessels from three fields of view with the greatest vascularization located on two different casts from the same patient. Under 100× magnification, we chose the sites of the greatest vascularity (hotspots), and individual microvessels were counted under 400× magnification. Each immunopositive structure (round, oval, and irregular) separated from other profiles or tissue elements was counted as a single vessel. Each single colored cell or a group of cells were considered a vessel regardless of the presence of vessel lumen. Vessels with visible muscular layer and morphotic elements apparent in the lumen were not counted as a microvessel. The final result was expressed as a number of vessels in the field of view under 400× magnification. The size of microscopic field was 0.236 mm^2^.

Statistical analysis {#Sec5}
--------------------

The acquired results were analyzed using SAS 9.4 software. The Chi-square test was used for binary variables. Comparison of continuous variables using Student's *t* test or Mann--Whitney test depending on their distribution demonstrated differences between groups. Kaplan--Meier analysis was used to draw total survival curves in groups depending on MVD value. Differences in survival were assessed using the log-rank test. Logistic regression model with odds ratios (OR) was used in the analysis of likelihood of survival. The level of significance was set at *p* \< 0.05. All values represent means ± SD.

Results {#Sec6}
=======

The MVD/CD34 and MVD/CD105 values {#Sec7}
---------------------------------

Analysis of CD34 expression conducted using Student's *t* test demonstrated significantly higher mean MVD/CD34 values in the tumor region (21.04 ± 6.47) compared to the normal control group (9.91 ± 1.67), (*t* = 5.87 for *p* = 0.001) and the dysplasia group (16.27 ± 3.25), (*t* = 2.36 for *p* = 0.02). Similar results were obtained for the assessment of endoglin (CD105) expression. Student's *t* test confirmed a significantly higher mean MVD/CD105 ratio within the tumor (14.04 ± 4.29) compared to the normal control group (2.5 ± 10), (*t* = 17.03 for \< 0.001) and the dysplasia group (9.00 ± 1.54), (*t* = 10.65 for *p* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}; Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).

Fig. 1Representative immunohistochemical staining of CD105. Isotype Ab control in specimen of HNSCC (**a**) (× 200), expression of CD105 in specimen of control oral mucosa (**b**) (× 200), expression of CD105 in specimen of dysplastic mucosa (**c**) (× 200), expression of CD105 in specimen of HNSCC (high MVD) (**d**) (× 100), and expression of CD105 in specimen of HNSCC (low MVD) (**e**) (× 200)

Table 2Results of MVD in the HNSCC group and the healthy controls (Student's *t* test)VariablesHNSCC patientsHealthy controlsTest Cochrano--Coxa*p* valueConfidence intervalAverageSDAverageSD− 95 to 95%MVD/CD 3421.046.479.911.6710.65\< 0.00019.03--13.21MVD/CD10514.044.292.51.0017.03\< 0.000110.18--12.89

Table 3Results of MVD in the HNSCC group and the dysplasia patients (Student's *t* test)VariablesHNSCC patientsDysplasia patientsTest Cochrano--Coxa*p* valueConfidence intervalAverageSDAverageSD− 95 to 95%MVD/CD 3421.046.4716.273.263.53\< 0.00012.01--7.52MVD/CD10514.044.299.001.556.54\< 0.00013.49--6.59

Table 4Results of MVD in the dysplasia patients and the healthy controls (Student's *t* test**)**VariablesHealthy controlsDysplasia patientsTest Cochrano--Coxa*p* valueConfidence intervalAverageSDAverageSD− 95 to 95%MVD/CD 349.921.6716.273.26− 5.80\< 0.00018.85--10.98MVD/CD1052.501.009.001.55− 11.84\< 0.000114.08--18.46

Analysis of significance of differences between patient groups {#Sec8}
--------------------------------------------------------------

The Mann--Whitney test demonstrated significantly lower MVD/CD34 ratios among patients with T3--T4 tumors compared to those with T1--T2 cancers (*U* = 442 for *p* = 0.01). This was an unexpected finding. However, no such relationship was found for the MVD/CD105 values and the demographic, clinical, and histopathological characteristics, such as age, sex, and histopathological grading (G feature) of the HNSCC patients, as shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}.

Fig. 2MVD/CD34 vs. tumor size. Comparison of patients with tumors T1--T2 vs. patients with T3--T4 tumors (Mann--Whitney test; *p* = 0,01). Box and whisker plot showing median, range of 25--75% and the min--max values

Fig. 3Representative immunohistochemical staining of CD34. Isotype Ab control in specimen of HNSCC (**a**), expression of CD34 (high MVD) in T1 tumor in specimen of HNSCC (**b**), and expression of CD34 (low MVD) in T4 tumor in specimen of HNSCC (**c**); (× 200)

Analysis of postoperative patient survival {#Sec9}
------------------------------------------

Five-year survival in the patients group was 45%. Taking into consideration the following characteristics: age, sex, histopathological grading, tumor size (T feature), clinical staging (TNM), MVD/CD34, and MVD/CD105, we built a multivariate logistic regression model containing characteristics considered significant for patient survival. No characteristics influencing probability of patient survival were identified. Kaplan--Meier analysis was used to obtain total survival curves for the patient groups divided based on the MVD values, and no differences in 5-year survival were found in relation to the MVD values.

Discussion {#Sec10}
==========

Remodeling of the existing vessels and formation of new ones is the key component of the neoplastic transformation, enabling the tumor to grow. Density of microvessels (MVD) reflects the intensity of angiogenesis within the tumor. In 1991, Weidner et al. proposed the MVD assessment as one of the measures of tumor vascularity \[[@CR9]\]. From the moment, Weidner et al. described a relationship between lymph node metastasis and MVD in breast cancer; many researchers have attempted to correlate MVD values with clinical and pathological factors in various types of neoplasms. A relationship was demonstrated between higher MVD and prognosis in non-small cell lung carcinoma, breast, and colon cancers \[[@CR10]--[@CR12]\]. However, some of the studies failed to show that MVD is a prognostic factor predicting patient survival \[[@CR13]\].

Many subsequent studies have used endothelial cell markers such as CD34 or CD105 for the analysis of MVD. In 2002, Schimming and Marme were the first to analyze MVD based on CD105 identification in HNSCC. They demonstrated a correlation between tumor size and the higher MVD/CD105 ratio in oral cancers \[[@CR14]\]. Based on this and similar studies, the concept emerged that the high MVD/CD105 values are associated with the presence of lymph node metastasis and poorer 5-year survival \[[@CR15]--[@CR19]\]. This and other studies \[[@CR20]\] suggested that CD105 expression might serve as an important prognostic factor in HNSCC, enabling the identification of patients at high risk of recurrence and shorter survival.

In this study, no statistically significant correlations were observed between the MVD values in HNSCCs and the tumor stage or other clinicopathological characteristics. Nor was there a correlation between the MVD values and patients' survival. This lack of correlations could be attributed to the use of TMAs for the MVD assessment. Since microvascularization differs within the tumor, MVD is usually averaged from several or several dozen places throughout tumor cross-section, whereas the TMA technique allows for microvessel assessment only in its selected fragments. Thus, TMAs might not fully reflect the true degree of microvascularization in a tumor, as also suggested by others \[[@CR21], [@CR22]\].

To the best of our knowledge, our study is the first to simultaneously assess MVD/CD105 and MVD/CD34 in HNSCC using TMAs. According to various reports, the results of MVD assessments using CD105 expression in HNSCCs vary over a wide range. In our data set, mean MVD in the study group was 61.34/mm^2^ for HNSCC and 2.61/mm^2^ for normal mucus membranes. Bodnar et al. reported higher MVD values in a group of patients with laryngeal cancers \[[@CR23]\]. Zvrko et al. reported results similar to our findings among patients with glottis and epiglottis cancers \[[@CR24], [@CR25]\]. However, Martone et al., Shimming et al., and Chien et al. reported lower MVD values \[[@CR14], [@CR17], [@CR26]\]. A wide range of values is also reported for the results of MVD assessment based on CD34 expression. In our results, mean MVD/CD34 was 21.46 (90.53 mm^2^) in HNSCC and 10.1 (42.61 mm^2^) in normal mucus membranes. Others have reported variable results \[[@CR27]--[@CR30]\].

Our results suggest that MVD, as currently measured, does not accurately reflect the degree of tumor vascularity. The higher MVD/CD34 values in the T1--T2 compared to T3--T4 cancers are counterintuitive and suggest that the current practice of using CD34 as a marker of MVD may be questioned. CD34 is expressed on hematopoietic cells, including early progenitor cells, and its abundance on microvessels in T1--T2 HNSCCs could be taken as an indication of an early differentiation stage of endothelial cells in the newly forming vessels. On the other hand, anti-CD34 Ab is considered as the "para-endothelial Ab" that reacts with antigens located on the surface of all endothelial cells regardless of their functional status. It was also demonstrated that anti-CD34 Abs react with the largest number of endothelial cells compared to other commonly used Abs \[[@CR21]\]. Indeed, in this study, the highest MVD values were obtained by analyzing CD34 expression, and the lowest values were obtained for CD105. It is generally thought that endoglin (CD105) rather than CD34 is expressed in the vascular endothelium of tumor vessels forming de novo \[[@CR8]\]. The role of CD34 and endoglin as potential markers of new vessels vs. functioning, mature vessels is currently unclear. Given the different specificities of anti-CD34 and anti-CD105 antibodies for endothelial cells, this is not surprising. Further studies will be necessary to establish which of the two proteins will emerge as a more reliable marker of all vessels and thus a more suitable marker for measurements of MVD in all tumors.

The variability of the MVD data in the literature suggests a need for a closer scrutiny of the reasons behind these discrepancies. The most critical concerns relate to: (a) the disease heterogeneity, emphasized by the fact that HNSCC is a disease encompassing several distinct sites and tumor histologies; (b) the antibodies used for MVD assessments vary in their quality and specificity; (c) methods for the tissue selection and handling differ; and (d) the assessment algorithms used to quantify MVDs are selected using disparate criteria that are based on the experience of individual investigators. There is an unmet need for applying a uniform IHC methodology to MVD assessments, including the use of antibodies that are specific for all endothelial cells and are appropriately used according to the standard experimental protocol. Currently, neither endoglin nor CD34 expression adequately reflects true MVD values in tumor tissues, and the use of Abs to both antigens may be necessary to achieve realistic results. Additional studies in larger patient cohorts with antibodies specific for all endothelial cells are to define the role of MVD as a predictive parameter in HNSCC and other malignancies.
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